Scilla Cuore 2022
22nd edition of the update and discussion event involving key leaders of the Italian cardiovascular clinic and research
Scilla Cuore 2022
22nd edition of the update and discussion event involving key leaders of the Italian cardiovascular clinic and research
The 2022 edition of Scilla Cuore proposes for the 22nd time a widely tested formula that sees numerous key leaders of Italian cardiology and related disciplines as protagonists in the dual function of providing professional updating and engaging scientific comparison on the hottest topics of clinical practice and research. The scientific program offers a wide range of widely debated topics, from female specificity in cardiovascular disease to news on heart failure and arrhythmias.
The 2022 edition of Scilla Cuore proposes for the 22nd time a widely tested formula that sees numerous key leaders of Italian cardiology and related disciplines as protagonists in the dual function of providing professional updating and engaging scientific comparison on the hottest topics of clinical practice and research. The scientific program offers a wide range of widely debated topics, from female specificity in cardiovascular disease to news on heart failure and arrhythmias.
interviews
Deficit di ferro riduce la sopravvivenza nello scompenso con componente infiammatoria
it
Prof. Piergiuseppe Agostoni
Defense from the pandemic: the keys are knowledge and trust in science
it
Prof. Giuseppe Novelli
Statins for over 65s: 30% reduction in heart attack risk
it
Prof. Raffaele Bugiardini
Common trunk stenosis: angioplasty or surgical bypass?
it
Prof. Alfredo R. Galassi
Cardiovascular screening for all young people against sudden death
it
Prof. Francesco Fedele
Sacubitril-Valsartan, sottoutilizzato rispetto a potenzialità e ad evidenze in letteratura
en
Prof. Savina Nodari
ISCHEMIA study: stable angina, medical therapy vs angioplasty
it
Dr. Patrizia Presbitero
With the same severity of heart attack, the woman dies more than the man from heart failure
it
Prof. Raffaele Bugiardini
The cardiovascular consequences of oncological therapies in the short and long term
it
Dr. Nicola Maurea
Hypertrophic cardiomyopathies: evolution, risk assessment, management
it
Prof. Cesare De Gregorio
Transthyretin cardiac amyloidosis is now treatable. Early diagnosis needed
it
Prof. Gianluca Di Bella
Sudden death from congenital channelopathy in new mothers: what to do?
it
Dr. Maurizio Santomauro
The scores for the selection of candidates for dual antiplatelet therapy
it
Prof. Vincenzo Paravati
Development of the subcutaneous defibrillator and its use in clinical practice
it
Dr. Riccardo Cappato
From sleep apnea, increased blood pressure and cardiovascular risk
it
Dr. Pietro Lentini